Sionna Therapeutics' shares dropped about 92% following the failure of its Phase 2a PreciSION CF trial for SION-719, which did not meet the key sweat chloride reduction endpoint. The company announced it will not advance SION-719 as an add-on therapy despite having strong cash reserves of $268.3 million as of June 2026. This setback impacts Sionna's cystic fibrosis pipeline, which heavily depends on its NBD1 stabilizer programs. Investors who suffered losses are being encouraged to seek legal review for potential recovery options.
Telsey Advisory Group raised Abercrombie & Fitch's price target from $115 to $118, implying an 11.35% upside from the current share price of around $106. Meanwhile, Raymond James downgraded the stock from "Outperform" to "Market Perform," signaling e...
Barclays maintained an "Underweight" rating on Target's stock but raised its price target from $115 to $140, even though Target's shares trade above $161. This cautious stance reflects concerns that Target may underperform its peers despite a strong ...
Heng Chen Seng, a director at Sea Limited, sold 20,000 shares valued at $2.4 million. This insider sale may indicate personal portfolio adjustments but does not necessarily reflect company performance. Investors should monitor further insider activit...
Moderna and Merck announced successful Phase 3 trial results for their personalized mRNA melanoma vaccine combined with Keytruda, showing significant improvement in recurrence-free and distant metastasis-free survival. This marks the first positive l...
Full Truck Alliance reported a strong second quarter with earnings per share of $0.20, beating analyst expectations by 5.26%. The company saw a 4.4% increase in total net revenues to $498.4 million, driven by a 33.1% rise in transaction service reven...
